Overview

Rituximab Plus Bendamustine as Front Line Treatment in Frail Elderly (>70 Years) Patients With DLBCL: a Phase II Multicenter Study of the FIL

Status:
Unknown status

Trial end date:
2016-02-01

Target enrollment:

Participant gender:

Summary

The purpose of the study is to evaluate feasibility and efficacy of rituximab-bendamustine (R-B)combination in elderly patients affected by diffuse large B-cell lymphoma and defined as frail according to CGA.

Phase:

Phase 2

Details

Lead Sponsor:

Fondazione Italiana Linfomi ONLUS

Treatments:

Bendamustine Hydrochloride
Rituximab